Does preoperative positron emission tomography with computed tomography predict nodal status in endometrial cancer? A pilot study by Nayot, D. et al.
NAYOT et al.
CURRENT ONCOLOGY—VOLUME 15, NUMBER 3
123 123 123 123 123
SHORT COMMUNICATION
Copyright © 2008 Multimed Inc.
ABSTRACT
Fewer than 20% of women with endometrial cancer
have positive nodes, and an accurate noninvasive
imaging modality to assess lymph node status would
be helpful in selecting those who need lymphadenec-
tomy. The objective of this pilot study was to evalu-
ate positron emission tomography with computed
tomography (PET–CT) in predicting nodal status be-
fore surgery for endometrial cancer. Twelve patients
were enrolled at a single tertiary care centre. The sen-
sitivity and specificity of preoperative PET–CT in pre-
dicting nodal status were 53.3% and 99.6% respectively.
Using PET–CT, all metastatic nodes may not necessar-
ily be detected, especially nodes with microscopic dis-
ease. The sensitivity of this imaging modality has to
be improved before it can routinely be used in the
preoperative evaluation of endometrial cancer.
KEY WORDS
Positron emission tomography, PET, computed tomogra-
phy, CT, endometrial cancer, preoperative, lymph nodes
1. INTRODUCTION
Endometrial cancer is the most common gynecologic
malignancy and the fourth most common cancer af-
fecting women, with approximately 4100 new cases
estimated in Canada in 20071. Surgical staging, which
includes hysterectomy and bilateral salpingo-oophorec-
tomy (HBSO), with pelvic and para-aortic lymphadenec-
tomy, is recommended for patients at high risk for
extrauterine disease. However, that procedure requires
referral to a gynecologic oncologist at a tertiary care
center and is associated with potential complications,
including nerve and vessel injury and lymphocyst de-
velopment 2. Fewer than 20% of endometrial cancer
cases are estimated to have positive nodes3. An accu-
rate, noninvasive, preoperative imaging modality to
assess lymph node status would therefore be very help-
ful in selecting patients for a surgical staging proce-
dure that would include lymphadenectomy.
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The novel imaging modality18F-FDG (fluoro-
deoxyglucose) positron emission tomography (PET)
identifies tumours by differentiating the increased gly-
colytic rate of neoplastic cells as compared with nor-
mal cells. The concurrent use of computed tomography
(CT) provides precise localization of the tumour. Data
on preoperative combined PET–CT in predicting lymph
node status in endometrial cancer are limited. We con-
ducted a prospective pilot study of 18F-FDG PET with
CT in assessing pelvic and para-aortic lymph nodes in
women with high-risk endometrial cancer before sur-
gical staging.
2. PATIENTS AND MATERIALS
This prospective cohort study was approved by the
Health Sciences Research Ethics Board of the Uni-
versity of Western Ontario, Canada. The use of 18F-
FDG for the study was approved by Health Canada.
All eligible patients received a PET–CT scan
within 4 weeks before their surgery. The protocol in-
cluded an intravenous dose of 555 MBq 18F-FDG, and
at 60 minutes post injection of the FDG tracer, whole-
body PET with CT images of the abdomen and pelvis.
At 90 minutes from injection, furosemide 40 mg was
given to facilitate excretion of the 18F-FDG from the
urinary tract. At 120–150 minutes, patients under-
went delayed imaging of the abdomen and pelvis.
All PET–CT scans were interpreted by a single nu-
clear medicine consultant physician (A.D.). The ex-
aminations were performed on a Discovery DST
PET–CT scanner (GE Medical Systems, Milwaukee,
WI, U.S.A.). Lymph nodes were classified as “posi-
tive” or “negative” according to increased FDG up-
take in the pelvic or para-aortic nodal regions, and if
positive, a corresponding anatomic location was as-
signed according to the CT images. Standardized up-
take values (SUV) were obtained, but no specific SUV
threshold for lymph node positivity was found.
All surgical staging procedures were performed
by one of two gynecologic oncologists (J.S.K., M.S.C.).
The surgeons were not blinded to the preoperative PET–
CT; however, all surgeries were completed systemati-
cally, beginning with HBSO and followed by complete
pelvic and para-aortic lymphadenectomy from the deepPREOPERATIVE PET–CT IN ENDOMETRIAL CANCER
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circumflex iliac vein inferiorly to the renal vessels su-
periorly. The pathology report included lymph node counts
and indication of the presence or absence of metastatic
disease. Test characteristics of sensitivity, specificity,
and positive (PPV) and negative (NPV) predictive values
at both the patient and the nodal level were calculated.
3. RESULTS
Between May 2004 and November 2006, 12 patients
were enrolled. Mean age was 62.6 years (range: 55–
74 years). From these 12 patients, a total of 244 lymph
nodes were removed, including 167 pelvic nodes (15 per
patient on average) and 77 para-aortic nodes (7 per
patient on average). Nodes were positive in 3 patients
(stage IIIC), and negative in 9 (stage I or II disease).
At the patient level, preoperative PET–CT accu-
rately predicted nodal status (positive or negative) for
all patients in the study. All 3 who had metastatic nodal
disease (stage IIIC) were correctly identified by in-
creased FDG uptake in the pelvic or para-aortic nodal
regions on preoperative PET–CT, and all 9 patients who
did not have metastatic nodal disease (that is, stage I or
II) were correctly identified as having disease confined
to the uterus. As a result, the sensitivity, specificity,
and PPV and NPV for PET–CT in predicting nodal status
at the patient level were all 100%.
However, at the nodal level, we observed discrep-
ancies between PET–CT and surgical and pathologic
results in 2 patients. In one patient of these patients,
increased FDG uptake was seen in 1 left pelvic node
(SUV 16.1) and 4 left para-aortic nodes (average
SUV 16.0). At surgery, the left pelvic and para-aortic
nodes were grossly abnormal (enlarged). Final pathol-
ogy confirmed metastatic disease in 2 left pelvic
nodes, 3 left para-aortic nodes, and 1 right pelvic node,
the latter of which was normal in size. In the other
patient, increased FDG uptake was seen in 1 left pel-
vic node (SUV 5.5). At surgery, a cluster of 5 enlarged
left pelvic nodes was found. Final pathology confirmed
metastatic disease in 5 left pelvic nodes and 1 right
pelvic node. Only one other patient had a positive PET–
CT, with increased FDG uptake in 3 para-aortic nodes
(average SUV 7.2). Those nodes were grossly normal
at surgery, but were confirmed as having metastatic
disease on final pathology.
There was no consistent relationship between SUV
and the extent or size of metastatic nodal disease. At
the nodal level, PET–CT showed a sensitivity of 53.3%
(8/15) and a specificity of 99.6% (222/229) for detect-
ing pelvic and para-aortic nodes. The PPV was 88.9%
(8/9), and the NPV was 97.0% (235/244).
4. DISCUSSION
The results of the present study suggest that the sensi-
tivity of PET–CT may be insufficient for routine
preoperative use of this imaging modality. Very few
studies have considered PET evaluation of lymph nodes
in endometrial cancer specifically. Horowitz et al. re-
ported sensitivity and specificity of 67% and 94% re-
spectively 4, but only 2 patients had metastatic nodes,
and 1 had a false-negative PET study with a 1.0-cm
metastatic pelvic node. Chao et al. reported sensitivity
of 73% and specificity of 95% for metastatic pelvic
nodes with PET 5; however, when PET was interpreted
with concurrent magnetic resonance imaging (MRI) or
CT (that is, PET–CT, as in the present study), sensitiv-
ity and specificity improved to 85% and 100% respec-
tively. On the other hand, Suzuki et al. reported a
sensitivity of 0% for PET in detecting nodal metastases
in endometrial cancer 6. All of the patients in that study
had metastatic foci smaller than 6 mm, but CT or MRI
correctly identified 2 of 5 patients with metastatic pel-
vic nodes and the 1 patient with metastatic para-aortic
nodal disease.
Using PET–CT, a single enlarged metastatic node may
not be able to be distinguished from a cluster of meta-
static nodes—a problem that may not be clinically sig-
nificant, because preoperative identification of even 1
metastatic node would prompt complete lymphadenec-
tomy. However, 2 patients in our study had a single right
pelvic node with microscopic tumour that did not have
increased FDG uptake on PET–CT. In both cases, the right
pelvic nodes were grossly normal at surgery. If these had
been the only metastatic nodes present, the PET–CT would
have been falsely negative, and the nodes would have
been missed if these patients did not have a complete
lymphadenectomy.
Ideally, PET–CT should predict lymph node sta-
tus accurately enough to influence decision-making
about surgical staging. It must be sufficiently sensi-
tive that it can reliably select patients for lymphadenec-
tomy, but it must also have a negative predictive
value sufficiently high that it can obviate the need
for lymphadenectomy.
5. CONCLUSIONS
In this small pilot study, preoperative PET–CT appeared
insufficiently sensitive to detect all metastatic nodes,
especially those with microscopic foci of disease. At
this time, the evidence that PET–CT can reliably pre-
dict nodal metastases before surgery is insufficient,
and refinement of this imaging modality would be re-
quired before it can routinely be used in the preoperative
evaluation of endometrial cancer.
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